Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Soleno Therapeutics ( (SLNO) ) has issued an announcement.
During August 18-19, 2025, Soleno Therapeutics‘ senior management participated in a non-deal roadshow to engage with existing and potential investors. This event, hosted by Guggenheim Securities and Piper Sandler, aimed to highlight the company’s strategic positioning and the commercial potential of VYKAT XR, the first approved treatment for hyperphagia in PWS patients. The company emphasizes its strong intellectual property protection and significant market opportunity in the PWS sector, supported by a solid financial position to advance its commercial launch.
The most recent analyst rating on (SLNO) stock is a Buy with a $72.00 price target. To see the full list of analyst forecasts on Soleno Therapeutics stock, see the SLNO Stock Forecast page.
Spark’s Take on SLNO Stock
According to Spark, TipRanks’ AI Analyst, SLNO is a Underperform.
Soleno Therapeutics shows high risk due to its lack of revenue and reliance on external financing. However, it maintains a solid equity base and is experiencing positive technical momentum, suggesting speculative interest. The valuation is typical for an early-stage biotech, with potential upside reliant on successful R&D outcomes.
To see Spark’s full report on SLNO stock, click here.
More about Soleno Therapeutics
Soleno Therapeutics operates in the biotechnology industry, focusing on developing treatments for rare diseases. Their primary product, VYKAT XR, is approved for treating hyperphagia in patients with Prader-Willi syndrome (PWS), a rare genetic disorder. The company is positioned to address significant unmet needs within the PWS market, which presents a substantial commercial opportunity.
Average Trading Volume: 1,264,655
Technical Sentiment Signal: Buy
Current Market Cap: $3.81B
For a thorough assessment of SLNO stock, go to TipRanks’ Stock Analysis page.